Carboplatin AUC

DRUG4 trials

Sponsors

GlaxoSmithKline, Case Comprehensive Cancer Center, NYU Langone Health, Washington University School of Medicine

Conditions

Adenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionEndometrial CancerNeoplasms, BreastStage IIB Non-Small Cell Lung CancerStage IIIA Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IIIC Non-Small Cell Lung Cancer

Phase 1

Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)

TerminatedNCT01395537

Case Comprehensive Cancer CenterAdenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction

Start: 2011-08-31End: 2014-12-31Updated: 2019-03-19

Phase 2

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

TerminatedNCT01220128

GlaxoSmithKlineNeoplasms, Breast

Start: 2011-04-11End: 2014-11-14Updated: 2021-05-25

A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus

CompletedNCT02744898

NYU Langone HealthEndometrial Cancer

Start: 2016-07-31End: 2020-03-01Updated: 2023-09-26

Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

CompletedNCT03916419

Washington University School of MedicineStage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer +1

Start: 2019-06-20End: 2025-09-28Updated: 2025-11-12

Related Papers

Early ctDNA stratifies survival in locally advanced and oligometastatic lung cancer treated with radiotherapy.

2026-04-30

A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus.

2024-09-03

Pulmonary magnetic resonance-guided online adaptive radiotherapy of locally advanced: the PUMA trial.

2023-05-049 citations

Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study

Breast Cancer Research and Treatment2017-02-0722 citations